Skip to content
Tenfell
Awarded contract
Published 10 Jul 2026

NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026

NHS England · London

Key facts

Awarded
05 Jul 2026
Contract starts
31 Aug 2026
Contract ends
31 Aug 2028
Procedure
Open procedure (framework)
Buyer type
Central government

Awarded to 25 suppliers

SupplierValue
FRESENIUS KABI LIMITED—
Dr Reddy's Laboratories (UK) Ltd—
GlaxoSmithKline—
Janssen-Cilag Ltd—
Orifarm UK—
Pfizer Ltd—
Teva UK Ltd—
Abbvie Ltd—
Amgen Ltd—
Sandoz Ltd—
Thornton & Ross Ltd—
Accord-UK Ltd—
Galapagos Biotech UK Ltd—
Gedeon Richter UK Ltd—
Roche Products Ltd—
UCB Pharma Ltd—
Zentiva Pharma UK Ltd—
Milpharm Limited—
Biogen Idec Ltd.—
Organon Pharma (UK) Ltd.—
Samsung Bioepis Ltd—
Aventis Pharma Limited t/a Sanofi—
Celltrion Healthcare Limited—
BIOSIMILAR COLLABORATIONS IRELAND LIMITED—
SWEDISH ORPHAN BIOVITRUM LTD—

Description

NHS Branded Medicines Tranche B - Lot 1 - London & South of England - CM/PHR/25/5731 Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Find a Tender (Open Government Licence v3.0). Always read the original notice before responding.